loading page

Relatively mild symptoms after chronic intoxication with a double dose encorafenib: a case report
  • +1
  • Paola Mian,
  • Elvira Meussen,
  • Djura Piersma,
  • Nienke Lankheet
Paola Mian
Medisch Spectrum Twente
Author Profile
Elvira Meussen
Medisch Spectrum Twente
Author Profile
Djura Piersma
Medisch Spectrum Twente
Author Profile
Nienke Lankheet
Medisch Spectrum Twente
Author Profile


Introduction: Encorafenib (BraftoviTM) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, in combination with binimetinib (Mektovi ®). According to the product label of encorafenib, there are no specific treatment recommendations in case of an overdose. Case presentation: We report on a 63 year old man who ingested a double dose (900 mg) of encorafenib for 16 days. He developed overall minor chronic intoxication symptoms such as upset stomach, bloating, occasional vomiting and muscle pain. Based on the most occurring adverse events of encorafenib, liver values, kidney function parameters and QTc interval were measured. Kidney function parameters were normal, whereas liver values were slightly increased and QTc slightly prolonged. The plasma concentration 3 hours after the last dose was 2110 ng/mL. Conclusion: We describe the course of a case with a chronic toxicity during 16 days of double dose of encorafenib as well as the followed approach, which could be taken into account when treating a patient with encorafenib intoxication.

Peer review status:UNDER REVIEW

31 Aug 2020Submitted to British Journal of Clinical Pharmacology
04 Sep 2020Assigned to Editor
04 Sep 2020Submission Checks Completed
07 Sep 2020Reviewer(s) Assigned
22 Sep 2020Review(s) Completed, Editorial Evaluation Pending